Condition: Squamous Cell Carcinoma of External Auditory Canal · Locally Advanced Tumor · Sponsor: Eye & ENT Hospital of Fudan University
To evaluate the efficacy and safety of induction chemotherapy combined with tislelizumab as neoadjuvant therapy in patients with locally advanced squamous cell carcinoma of the external auditory canal; to explore the improvement in the preservation rate of important neurovascular structures (including the facial nerve, internal carotid artery canal, sigmoid sinus, and posterior cranial nerves, etc.).
This description comes directly from the study's public registry record.
Chunfu Dai · 021-64377134 · cfdai66@163.com
Xinmao Song · 021-34233877 · muqinger@sina.com
Always discuss trial participation with your own doctor first.
| Li Wang | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07370337